Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc.SLS · Entity 4313 | Director · President and CEO | June 16, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SELLAS Life Sciences Group, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,759,183 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 1,065,000 · Balance 1,759,183 F1: The Reporting Person received an award of 1,065,000 restricted stock units on June 16, 2026, which shall vest as follows: (i) 25% on December 1, 2026 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person received an award of 1,065,000 restricted stock units on June 16, 2026, which shall vest as follows: (i) 25% on December 1, 2026 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 18, 2026 20:30 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 1,065,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-075773 · tm2618312-1_4seq1.xml · nonDerivative · entry 1 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,759,183 F1 · shares: The Reporting Person received an award of 1,065,000 restricted stock units on June 16, 2026, which shall vest as follows: (i) 25% on December 1, 2026 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:05 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | OtherCommon Stock | 187,066 | $1.50 | $280,599.00 |
DisclosureSEC source: 0001104659-25-118872 · tm2532693-1_4seq1.xml · nonDerivative · entry 1 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 686,966 F1 · kind: Transaction relates to shares of common stock withheld by the SELLAS Life Sciences Group, Inc. (the "Issuer") to cover tax withholding obligations of the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs"). F2 · shares: Represents the number shares of common stock withheld by the Issuer to cover tax withholding obligations of the Reporting Person in connection with the vesting of RSUs. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 22:34 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 385,750 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001104659-25-003501 · tm253166-7_4seq1.xml · derivative · entry 3 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 385,750 Underlying: Common Stock · 385,750 shares Expires 2035-01-10 F3 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 10, 2025 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 22:34 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 243,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-003501 · tm253166-7_4seq1.xml · nonDerivative · entry 2 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 859,032 F2 · shares: The Reporting Person received an award of 243,900 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, provided that the Reporting Person remains in service with the Issuer through each such vesting date. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 22:34 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 257,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-003501 · tm253166-7_4seq1.xml · nonDerivative · entry 1 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 615,132 F1 · shares: The Reporting Person received an award of 257,000 restricted stock units on January 10, 2025, which shall vest as follows: (i) 25% on December 1, 2025 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. Read SEC document |
| December 04, 2024 Filed Dec 5, 2024 22:05 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | OtherCommon Stock | 28,289 | $1.13 | $31,966.57 |
DisclosureSEC source: 0001104659-24-125943 · tm2430303-2_4seq1.xml · nonDerivative · entry 1 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,132 F1 · kind: Transaction relates to shares of common stock withheld by the SELLAS Life Sciences Group, Inc. (the "Issuer") to cover tax withholding obligations of the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs"). F2 · shares: Represents the number shares of common stock withheld by the Issuer to cover tax withholding obligations of the Reporting Person in connection with the vesting of RSUs. Read SEC document |
| January 22, 2024 Filed Jan 25, 2024 11:04 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 238,500 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001104659-24-006410 · tm243935-5_4seq1.xml · derivative · entry 2 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,500 Underlying: Common Stock · 238,500 shares Expires 2034-01-22 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| January 22, 2024 Filed Jan 25, 2024 11:04 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 159,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-006410 · tm243935-5_4seq1.xml · nonDerivative · entry 1 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,421 F1 · shares: The Reporting Person received an award of 159,000 restricted stock units on January 22, 2024, which shall vest as follows: (i) 25% on December 1, 2024 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 21:10 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | OtherClass A Common Stock | 12,268 | $1.08 | $13,249.44 |
DisclosureSEC source: 0001104659-23-124688 · tm2332459-3_4seq1.xml · nonDerivative · entry 1 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,421 F1 · kind: Transaction relates to shares of common stock withheld by SELLAS Life Sciences Group, Inc. (the "Issuer") to cover tax withholding obligations of the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs"). F2 · shares: Represents the number shares of common stock withheld by the Issuer to cover tax withholding obligations of the Reporting Person in connection with the vesting of RSUs. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:15 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 217,500 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0001104659-23-010638 · tm235353d7_4seq1.xml · derivative · entry 2 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,500 Underlying: Common Stock · 217,500 shares Expires 2033-02-02 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the February 2, 2023 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:15 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 58,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-010638 · tm235353d7_4seq1.xml · nonDerivative · entry 1 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,689 F1 · shares: The Reporting Person received an award of 58,000 restricted stock units on February 2, 2023, which shall vest as follows: (i) 25% on December 1, 2023 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.date. Read SEC document |
| December 05, 2022 Filed Dec 5, 2022 21:14 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | SaleClass A Common Stock | 6,494 | $2.61 | $16,938.30 |
DisclosureSEC source: 0001104659-22-124568 · tm2232008-3_4seq1.xml · nonDerivative · entry 1 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,689 F1 · shares: Represents the number shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reflects the weighted average sale price of the shares of common stock sold. These shares of common stock were sold in multiple transactions at prices ranging from $2.58 to $2.66, inclusive, per share of common stock. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares of common stock sold at each price. Read SEC document |
| January 31, 2022 Filed Feb 1, 2022 22:06 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 165,000 | $0.00 Strike: $5.34 | $0.00 |
DisclosureSEC source: 0001104659-22-010396 · tm225088-3_4seq1.xml · derivative · entry 2 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2032-01-31 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 31, 2022 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| January 31, 2022 Filed Feb 1, 2022 22:06 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 44,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-010396 · tm225088-3_4seq1.xml · nonDerivative · entry 1 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,167 F1 · shares: The Reporting Person received an award of 44,000 restricted stock units on January 31, 2022, which shall vest as follows: (i) 25% on December 1, 2022 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 22:15 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | SaleCommon Stock | 2,120 | $6.25 | $13,251.91 |
DisclosureSEC source: 0001104659-21-146424 · tm2134552-6_4seq1.xml · nonDerivative · entry 1 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,167 F1 · shares: Represents the number shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reflects the weighted average sale price of the shares of common stock sold. These shares of common stock were sold in multiple transactions at prices ranging from $6.25 to $6.27, inclusive, per share of common stock. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares of common stock sold at each price. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:26 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 118,500 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001104659-21-033287 · tm218923-1_4.xml · derivative · entry 2 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,500 Underlying: Common Stock · 118,500 shares Expires 2031-03-04 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 4, 2021 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:26 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 19,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-033287 · tm218923-1_4.xml · nonDerivative · entry 1 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,287 F1 · shares: The Reporting Person received an award of 19,750 restricted stock units on March 4, 2021, which shall vest as follows: (i) 25% on December 1, 2021 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. Read SEC document |
| March 12, 2020 Filed Mar 17, 2020 01:18 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001104659-20-034286 · tm2012902-3_form4.xml · derivative · entry 2 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-03-12 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 12, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| March 12, 2020 Filed Mar 17, 2020 01:18 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 95,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-034286 · tm2012902-3_form4.xml · nonDerivative · entry 1 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 F1 · shares: The reporting person received an award of 95,000 restricted stock units on March 12, 2020, which shall vest as follows: (i) 50% on meeting the primary endpoint in Phase 3 REGAL study, provided that if such endpoint is met prior to March 12, 2021, such vesting will not occur until March 12, 2021 and (ii) 50% upon approval by the FDA of galinpepimut-S. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 23:02 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 425,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0000899243-19-008199 · doc4.xml · derivative · entry 1 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,000 Underlying: Common Stock · 425,000 shares Expires 2029-03-14 F1 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 14, 2019 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 02:03 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | SaleCommon Stock | 23,277 | $1.25 | $29,189.36 |
DisclosureSEC source: 0001209191-19-001612 · doc4.xml · nonDerivative · entry 1 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,858 F1 · shares: The Reporting Person sold such shares to cover personal income tax liability. F2 · price: The price reported is a weighted average price. The shares were sold at prices ranging from $1.23 to $1.31 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 23:56 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $5.24 | $0.00 |
DisclosureSEC source: 0001209191-18-020013 · doc4.xml · derivative · entry 1 Stergiou Angelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2028-03-12 F1 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 13, 2018 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 22:12 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 450,135 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-067660 · doc4.xml · nonDerivative · entry 1 Stergiou Andelos M. · CIK 0001724253 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,135 F1 · price: Received in exchange for common shares of SELLAS Life Sciences Group, Ltd ("SELLAS") in connection with the merger of SELLAS and a wholly owned indirect subsidiary of Issuer (then known as Galena Biopharma, Inc.) (the "Merger"). On the effective date of the Merger, each common share of SELLAS was converted into 43.9972 shares of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.